FDA clears Meriglu Topical Skin Adhesive through the 510(k) pathway
FDA review of Meriglu Topical Skin Adhesive ended with a substantial equivalence finding, placing the device within the agency’s Class II framework for a tissue adhesive for the topical approximation of skin. The decision positions the product inside a long-established category used to close superficial skin edges without sutures or staples, where the regulatory question is not whether the technology is novel, but whether it performs similarly enough to an already cleared device to justify market entry under the 510(k) route.
This device sits under regulation number 878.4010 and product code MPN. In practical regulatory terms, the clearance means the agency accepted the device as sufficiently comparable to existing topical skin adhesives for its intended use. For clinicians, that category generally matters when wound edges are straightforward to approximate and when a rapid closure method is preferred over more time-consuming closure techniques. The underlying clinical logic is simple: a polymeric adhesive can create an external barrier over approximated skin, helping hold the wound edges together while the tissue heals.
Meriglu’s clearance also adds another manufacturer to an already populated device class. Chemence Medical, Connexicon Medical, Okapi Medical doing business as Resivant Medical, and Optmed also appear in the same TPLC record for substantially equivalent premarket reviews in this category. Meriglu is listed with a single 510(k) entry, K230981, under M/S. Meril Endo Surgery Private Limited. The record does not describe the engineering details of the adhesive, the exact formulation chemistry, or any head-to-head clinical superiority claims. What it does show is the regulatory endpoint: the device met the threshold for substantial equivalence in a class where the benchmark is comparability to existing marketed products.
Why skin adhesives continue to attract regulatory clearance
Topical skin adhesives occupy a narrow but clinically useful space in wound closure. They offer a noninvasive alternative for selected lacerations and incisions where low-tension skin approximation is possible. When a closure method avoids needle puncture and knot tying, it can reduce procedure time and eliminate suture removal visits. In outpatient medicine, emergency care, minor surgery, and procedural dermatology, that convenience can matter as much as the closure itself.
The biological rationale is straightforward. After wound edges are brought together, an adhesive film can serve as a mechanical bridge, limiting edge separation while the epidermis re-epithelializes. The adhesive does not replace the biology of healing; it supports it. Its value depends on correct wound selection, careful skin approximation, and avoiding situations where moisture, tension, or motion would overwhelm the seal. In that sense, the device is only as effective as the wound it is chosen for.
FDA’s classification of these products as Class II reflects a familiar balance of utility and risk. These devices are not treated as experimental tools; they are established closure options that require performance controls but not the more burdensome premarket approval process reserved for higher-risk technologies. A 510(k) clearance does not certify superiority. It certifies equivalence to a predicate in terms of intended use and technological characteristics, or that any differences do not raise new questions of safety or effectiveness.
A crowded category with familiar safety questions
The TPLC record also shows that tissue adhesives do not exist in a vacuum. The same product category has generated recalls, including a Class II action for Ethicon in 2021 and a Class III action for McKesson Medical-Surgical in 2022. Those entries do not describe Meriglu’s own performance, but they do remind clinicians that devices in this space can be vulnerable to packaging, labeling, distribution, or quality-control issues even when the core technology is familiar.
For bedside use, the main safety issues remain tied to application rather than headline-making engineering claims. Adhesives can fail if placed across wounds under too much tension, if they are exposed to premature moisture, or if they are used on wounds that should be closed by another method. Misapplication can lead to dehiscence, irritation, or delayed healing. The regulatory record itself does not list adverse events for this product, so any safety judgment must stay anchored to the device class rather than to unreported outcomes.
One sentence captures the clinical reality: topical adhesives are useful only when the wound is the right kind of wound.
For surgeons, emergency physicians, and procedural clinicians, Meriglu’s clearance is best read as an addition to an existing closure toolbox rather than as a shift in standard practice. The decision expands the list of commercially available options within a familiar category, but it leaves the core questions unchanged: how the adhesive behaves on real skin, how reliably it holds under ordinary movement, and how consistently the product can be manufactured and supplied over time.
The FDA record provides no patient-level trial data, no comparative healing outcomes, and no postmarket effectiveness claims. It does, however, confirm that Meriglu Topical Skin Adhesive cleared the agency’s substantial equivalence standard as a Class II topical skin adhesive. What remains unresolved is not whether the device fits the category, but how it will perform in routine clinical hands once it moves beyond the regulatory file and into everyday wound closure practice.